Quick Summary
- ARK Invest purchased roughly $19.4M worth of CoreWeave shares after the stock dropped 19% following its Q4 earnings announcement
- Kratos Defense & Security Solutions represented the largest single trade at $23.2M in new share acquisitions
- The fund trimmed its Teradyne position by $12.9M, continuing a recent trend of reducing exposure
- Rocket Lab shares were sold despite strong earnings performance, as the stock fell approximately 5%
- Other transactions included selling Roku shares and initiating a Generate Biomedicines position
Cathie Wood’s ARK Invest made several notable portfolio changes on Thursday, February 27, executing both new investments and position reductions across technology, defense, and biotech industries.
The trading day’s largest purchase centered on Kratos Defense & Security Solutions. ARK bought 252,169 shares worth $23.2 million. This company focuses on unmanned aerial systems and autonomous defense technology, fitting well within ARK’s investment approach emphasizing robotics and automation innovation.
CoreWeave represented ARK’s second-largest buy of the day. The AI cloud infrastructure specialist saw ARK purchase 198,980 shares totaling roughly $19.4 million across its ARKK and ARKW funds.
CoreWeave, Inc. Class A Common Stock, CRWV
The CoreWeave investment came during a challenging trading session for the stock, which plunged 19%. This decline followed the company’s fourth-quarter results, which showed strong revenue performance but also highlighted widening losses and higher-than-anticipated capital spending.
ARK’s decision to buy during the selloff suggests the fund views the negative market response as short-term noise rather than a reflection of underlying business problems. CoreWeave serves the rapidly growing AI computing infrastructure market, which continues to see strong demand trends.
CoreWeave holds a Moderate Buy consensus from Wall Street analysts. The stock has received eleven Buy recommendations and eight Hold ratings, with an average price target of $114.18 indicating roughly 43.5% upside potential from present levels.
ARK Scales Back Teradyne and Rocket Lab Holdings
On the selling side, ARK offloaded 38,773 Teradyne shares worth $12.9 million across multiple ETFs. The company produces semiconductor testing equipment and industrial automation solutions. This sale represents a continuation of ARK’s recent strategy to reduce its Teradyne holdings.
The fund also sold 46,921 Rocket Lab shares valued at roughly $3.4 million. This came after the aerospace firm reported quarterly results that exceeded both profit and revenue expectations, though shares still dropped about 5% during Friday’s session.
Rocket Lab reported strong launch activity and a growing order pipeline. However, the company pushed back the first launch of its larger Neutron rocket to late 2026, which may have disappointed some investors.
Additional Portfolio Adjustments in Biotech and Technology
ARK sold 46,389 Roku shares worth $4.3 million from its ARKK fund. The firm did not provide public commentary on the reasoning behind this sale.
In biotechnology, ARK purchased 459,525 shares of Generate Biomedicines worth $7.4 million through its ARKG fund. At the same time, the fund sold 39,423 Ionis Pharmaceuticals shares for $3.2 million.
ARK also divested 10,590 Deere & Co shares for $6.6 million and trimmed its Guardant Health holdings by 27,334 shares worth $2.7 million.
Smaller moves included selling 205,211 PagerDuty shares for $1.5 million and buying 14,097 Brera Holdings shares valued at roughly $15,600.
The CoreWeave and Kratos purchases stood out as ARK’s two largest individual trades on February 27, totaling more than $42 million in combined value.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
